Nebivolol: third-generation β-blockade

Bibliography

• McNEELY W, GOA KL: Nebivolol in the management of essential hypertension: a review. Drugs (1999) 57(4):633-651.
   PubMed Web of Science ®Google Scholar
• COCKCROFT J: Nebivolol: a review. Expert Opin. Pharmacother. (2004) 5(4):893-899.
   Google Scholar
• THUILLEZ C, RICHARD V: Targeting endothelial dysfunction in hypertensive subjects. J. Hum. Hypertens. (2005) 19(Suppl. 1):S21-S25.
   Web of Science ®Google Scholar
• WEBER MA: The role of the new β-blockers in treating cardiovascular disease. Am. J. Hypertens. (2005) 12(Pt. 2):169S-176S.
   Google Scholar
• SULE SS, FRISHMAN W: Nebivolol: new therapy update. Cardiol. Rev. (2006) 14(5):259-264.
   PubMedGoogle Scholar
• MOEN MD, WAGSTAFF AJ: Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs (2006) 66(10):1389-1409.
   PubMed Web of Science ®Google Scholar
• VEVERKA A, NUZUM DS, JOLLY JL: Nebivolol: a third-generation β-adrenergic blocker. Ann. Pharmacother. (2006) 40(7-8):1353-1360.
   PubMed Web of Science ®Google Scholar
• LINDHOLM LH, CARLBERG B, SAMUELSSON O: Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 366(9496):1545-1553.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, GOMMEREN W, VAN LOMMEN G, JANSSEN PA, LEYSEN JE: The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β-adrenergic blockers. Mol. Pharmacol. (1988) 34(6):843-851.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, VAN GOMPEL P, LEYSEN JE: Human β1- and β2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known β-adrenergic blockers. Biochem. Pharmacol. (1991) 42(9):1683-1689.
   PubMedGoogle Scholar
• VAN NUETEN L, DE CREE J: Nebivolol: comparison of the effects of DL-nebivolol, D-nebivolol, L-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc. Drugs. Ther. (1998) 12(4):339-444.
   PubMedGoogle Scholar
• MANGRELLA M, ROSSI F, FICI F, ROSSI F: Pharmacology of nebivolol. Pharmacol. Res. (1998) 38(6):419-431.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR: β-Adrenergic receptor blockade in chronic heart failure. Circulation (2000) 101:558-569.
   PubMed Web of Science ®Google Scholar
• PESSINA AC: Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 3):S33-S35.
   Google Scholar
• IGNARRO LJ, BYRNS RE, TRINH K, SISODIA M, BUGA GM: Nebivolol: a selective β(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide (2002) 7(2):75-82.
   PubMed Web of Science ®Google Scholar
• RITTER JM: Nebivolol: endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 3):S13-S16.
   PubMed Web of Science ®Google Scholar
• VAN MERODE T, VAN BORTEL LM, SMEETS FA et al.: Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J. Hypertens. (1989) 7(Suppl. 6):S262-S263.
   Google Scholar
• GOLDSTEIN M, VINCENT JL, DE SMET JM et al.: Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function. J. Cardiovasc. Pharmacol. (1993) 22(2):253-258.
   PubMedGoogle Scholar
• HIMMELMAN A, HEDNER T, SNOECK E, LUNDGREN B, HEDNER J: Hemodynamic effects and pharmacokinetics of oral D- and L-nebivolol in hypertensive patients. Eur. J. Clin. Pharmacol. (1997) 51:493-498.
   PubMedGoogle Scholar
• DE CREE J, VAN ROOY P, GEUKENS H, HAEVERANS K, VERHAEGEN H: The antihypertensive and cardiac hemodynamic effects of nebivolol. Angiology (1992) 43(5):369-377.
   PubMedGoogle Scholar
• BOWMAN AJ, CHEN CP, FORD GA: Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmacol. (1994) 38(3):199-204.
   PubMed Web of Science ®Google Scholar
• COCKCROFT JR, CHOWIENCZYK PJ, BRETT SE, et al.: Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. (1995) 274(3):1067-1071.
   PubMed Web of Science ®Google Scholar
• TZEMOS N, LIM PO, MACDONALD TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation (2001) 104(5):511-514.
   PubMed Web of Science ®Google Scholar
• CHLOPICKI S, KOZLOVSKI VI, GRYGLEWSKI RJ: NO-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by β-adrenoceptors or by 5 HT1A-receptors. J. Physiol. Pharmacol. (2002) 53(4 Pt 1):615-624.
   PubMedGoogle Scholar
• KALINOWSKI L, DOBRUCKI LW, SZCZEPANSKA-KONKEL M et al.: Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation (2003) 107(21):2747-2752.
   PubMed Web of Science ®Google Scholar
• BROEDERS MA, DOEVENDANS PA, BEKKERS BC et al.: Nebivolol: a third-generation β-blocker that augments vascular nitric oxide release: endothelial β(2)-adrenergic receptor-mediated nitric oxide production. Circulation (2000) 102(6):677-684.
   PubMed Web of Science ®Google Scholar
• DE GROOT AA, MATHY MJ, VAN ZWIETEN PA, PETERS SL: Involvement of the β3-adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol. (2003) 42(2):232-236.
   PubMedGoogle Scholar
• DESSY C, SALIEZ J, GHISDAL P et al.: Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation (2005) 112(8):1198-1205.
   PubMed Web of Science ®Google Scholar
• GALDERISI M, CICALA S, D'ERRICO A, DE DIVITIIS O, DE SIMONE G: Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J. Hypertens. (2004) 22(11):2201-2208.
   PubMed Web of Science ®Google Scholar
• TOGNI M, VIGORITO F, WINDECKER S et al.: Does the β-blocker nebivolol increase coronary flow reserve? Cardiovasc. Drugs Ther. (2007) [Epub published ahead of print].
   PubMedGoogle Scholar
• ERDOGAN D, GULLU H, CALISKAN M et al.: Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart (2006) 93(3):319-324.
   PubMedGoogle Scholar
• VAN DE WATER A, JANSSENS W, VAN NEUTEN J et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective β1-adrenergic antagonist. J. Cardiovasc. Pharmacol. (1988) 11(5):552-563.
   Google Scholar
• VAN DE WATER A, XHONNEUX R, RENEMAN RS, JANSSEN PA: Cardiovascular effects of DL-nebivolol and its enantiomers – a comparison with those of atenolol. Eur. J. Pharmacol. (1988) 156(1):95-103.
   PubMedGoogle Scholar
• SACHSE C, BROCKMULLER J, BAUER S et al.: Cytochrome P450 2D variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Gen. (1997) 60:284-295.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE J, POIRIER L, POIRIER P, TURGEON J, LACOURCIERE Y: The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br. J. Clin. Pharmacol. (2006) 63(5):575-582.
   PubMedGoogle Scholar
• SHAW AA, ZIEMNIAK J, LIU S et al.: Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers. Clin. Pharmacol. Ther. (2005) 77:P77 (abstract).
   Google Scholar
• SHAW AA, BLAND TM, TU HC : et al.: Single-dose, relative bioavailability and food effect study of nebivolol hydrochloride in healthy volunteers characterized according to their metabolizing status. AAPS Pharm. Sci. Online Journal (2003) 5:W5238 (Abstr.).
   Google Scholar
• SHAW AA, LIU S, CHERVENICK SW et al.: Effects of hepatic impairment on the pharmacokinetic disposition of nebivolol: a dual acting nitric oxide modulator/cardioselective 1-antagonist. Clin. Pharmacol. Ther. (2005) 77:P41 (abstract).
   Google Scholar
• SHAW AA, LIU S, ZACHWIEJA LF et al.: Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol. Clin. Pharmacol. Ther. (2005) 77:P38 (Abstr.).
   Google Scholar
• CHEYMOL G, WOESTENBORGHS R, SNOECK E et al.: Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur. J. Clin. Pharmacol. (1997) 51(6):493-498.
   PubMed Web of Science ®Google Scholar
• DE CREE J, COBO C, GEUKENS H, VERHAEGEN H: Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol and nebivolol. Angiology (1990) 41(2):95-105.
   PubMedGoogle Scholar
• VAN NUETEN L, DE CREE J: Nebivolol: comparison of the effects of DL-nebivolol, D-nebivolol, L-nebivolol, atenolol and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc. Drugs. Ther. (1998) 12(4):339-444.
   PubMedGoogle Scholar
• DE CREE J, VAN ROOY P, GEUKENS H, HAEVERANS K, VERHAEGEN H: The antihypertensive and cardiac hemodynamic effects of nebivolol. Angiology (1992) 43(5):369-377.
   PubMedGoogle Scholar
• DE CREE J, VAN NUETEN L, GEUKENS H, VERHAEGEN H: Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int. J. Clin. Pharmacol. Res. (1992) 12(4):159-163.
   PubMedGoogle Scholar
• CHAN TY, WOO KS, NICHOLLS MG: The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study. Int. J. Cardiol. (1992) 35(3):387-395.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, DUPONT AG, VERTOMMEN C, GOYVAERTS H, ROBERTSON JI: A dose-response trial of nebivolol in essential hypertension. J. Hum. Hypertens. (1997) 11(2):139-144.
   PubMedGoogle Scholar
• VAN NUETEN L, TAYLOR FR, ROBERTSON JI: Nebivolol versus atenolol and placebo in essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. (1998) 12(2):135-140.
   PubMedGoogle Scholar
• GRASSI G, TREVANO FQ, FACCHINI A, TOUTOUZAS T, CHANU B, MANCIA G: Efficacy and tolerability profile of nebivolol versus atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood. Press. (2003) 2(Suppl.):35-40.
   Google Scholar
• UHLÍR O, FEJFUSA M, HAVRANEK K et al.: Nebivolol versus metoprolol in the treatment of hypertension. Drug. Invest. (1991) 3(Suppl. 1):107-110.
   Google Scholar
• CZURIGA I, RIECANSKY I, BODNAR J et al.: For The NEBIS Investigators; NEBIS Investigators Group: comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc. Drugs Ther. (2003) 17(3):257-263.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, SCHELLING A, VERTOMMEN C, DUPONT AG, ROBERTSON JI: Nebivolol versus enalapril in the treatment of essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. (1997) 11(12):813-819.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, RISHOJ NIELSEN M, VERTOMMEN C, DUPONT AG, ROBERTSON JI: Nebivolol versus enalapril in essential hypertension: a long-term double-blind comparative trial. Acta. Clin. Belg. (1999) 54(1):19-25.
   PubMedGoogle Scholar
• AGABITI ROSEI EA, RIZZONI D, COMINI S, BOARI G; NEBIVOLOL-LISINOPRIL STUDY GROUP: Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press. Suppl. (2003) 1:30-35.
   Google Scholar
• LACOURCIERE Y, LEFEBVRE J, POIRIER L, ARCHAMBAULT F, ARNOTT W: A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am. J. Ther. (1994) 1(1):74-80.
   PubMedGoogle Scholar
• LACOURCIERE Y, POIRIER L, LEFEBVRE J, PROVENCHER P, ARNOTT W: Comparative effects of a new cardioselective β-blocker nebivolol and nifedipine sustained-release on 24-h ambulatory blood pressure and plasma lipoproteins. J. Clin. Pharmacol. (1992) 32(7):660-666.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN L, LACOURCIERE Y, VYSSOULIS G et al.: Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am. J. Ther. (1998) 5(4):237-243.
   PubMedGoogle Scholar
• MAZZA A, GIL-EXTREMERA B, MALDONATO A, TOUTOUZAS T, PESSINA AC: Nebivolol versus amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. (2002) 11(3):182-188.
   PubMed Web of Science ®Google Scholar
• VAN BORTEL LM, BULPITT CJ, FICI F: Quality of life and antihypertensive effect with nebivolol and losartan. Am. J. Hypertens. (2005) 18(8):1060-1066.
   PubMedGoogle Scholar
• BRUNE S, SCHMIDT T, TEBBE U, KREUZER H: Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology (1990) 41(9 Pt. 1):696-701.
   PubMed Web of Science ®Google Scholar
• WISENBAUGH T, KATZ I, DAVIS J et al.: Long-term (3-month) effects of a new β-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J. Am. Coll. Cardiol. (1993) 21(5):1094-1100.
   PubMed Web of Science ®Google Scholar
• UHLIR O, DVORAK I, GREGOR P et al.: Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J. Card. Fail. (1997) 3(4):271-276.
   PubMedGoogle Scholar
• BREHM BR, WOLF SC, GORNER S, BUCK-MULLER N, RISLER T: Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur. J. Heart. Fail. (2002) 4(6):757-763.
   PubMed Web of Science ®Google Scholar
• ROUSSEAU MF, CHAPELLE F, VAN EYLL C et al.: Medium-term effects of β-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J. Card. Fail. (1996) 2(1):15-23.
   PubMedGoogle Scholar
• KAMP O, SIESWERDA GT, VISSER CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. J. Cardiol. (2003) 92(3):344-348.
   PubMed Web of Science ®Google Scholar
• NODARI S, METRA M, DEI CAS L: β-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol versus nebivolol. Eur. J. Heart Fail. (2003) 5(5):621-627.
   PubMed Web of Science ®Google Scholar
• PATRIANAKOS AP, PARTHENAKIS FI, MAVRAKIS HE et al.: Comparitive efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy: a 12-month study. Am. Heart J. (2005) 150(5): 985.
   PubMed Web of Science ®Google Scholar
• LOMBARDO RM, REINA C, ABRIGNANI MG, RIZZO PA, BRASCHI A, DE CASTRO S: Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am. J. Cardiovasc. Drugs (2006) 6(4):259-263.
   PubMedGoogle Scholar
• EDES I, GASIOR Z, WITA K: Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur. J. Heart. Fail. (2005) 7(4):631-639.
   PubMed Web of Science ®Google Scholar
• FLATHER MD, SHIBATA MC, COATS AJ et al; ON BEHALF OF THE SENIORS INVESTIGATORS: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. (2005) 26(3):215-225.
   PubMed Web of Science ®Google Scholar
• GHIO S, MARGRINI G, SERIO A et al.: Effects of nebivolol in elderly heart failure patienst with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur. Heart. J. (2006) 27(5):562-568.
   PubMed Web of Science ®Google Scholar
• DE GROOT AA, MATHY MJ, VAN ZWIETEN PA, PETERS SL: Antioxidant activity of nebivolol in the rat aorta. J. Cardiovasc. Pharmacol. (2004) 43(1):148-153.
   PubMedGoogle Scholar
• MOLLNAU H, SCHULZ E, DAIBER A et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. (2003) 23(4):615-621.
   PubMed Web of Science ®Google Scholar
• OELZE M, DAIBER A, BRANDES RP et al.: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension (2006) 48(4):677-684.
   PubMed Web of Science ®Google Scholar
• MASON RP, KUBANT R, JACOB RF, WALTER MF, BOYCHUK B, MALINSKI T: Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J. Cardiovasc. Pharmacol. (2006) 48(1):862-869.
   PubMed Web of Science ®Google Scholar
• TROOST R, SCHWEDHELM E, ROJCZYK S, TSIKAS D, FRÖLICH JC: Nebivolol reduces oxidative stress in healthy volunteers. Br. J. Pharmacol. (2000) 50(4):377-339.
   Google Scholar
• FRATTA PASINI A, GARBIN U, NAVA MC et al.: Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens. (2005) 23(3):589-59.
   PubMedGoogle Scholar
• CELIK T, IYISOY A, KURSAKLIOGLU H et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. (2006) 24(3):591-596.
   PubMed Web of Science ®Google Scholar
• MASON RP, KALINOWSKI L, JACOB RF, JACOBY AM, MALINSKI T: Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium in black Americans. Circulation (2005) 112:3795-3801.
   PubMed Web of Science ®Google Scholar
• POIRIER L, CLEROUX J, NADEAU A, LACOURCIERE Y: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. (2001) 19(8):1429-1435.
   PubMed Web of Science ®Google Scholar
• CLEOPHAS TJ, GRABOWSKY I, NIEMEYER MG, MAKEL WM, VAN DER WALL EE; NEBIVOLOL FOLLOW-UP STUDY GROUP: Paradoxical pressor effects of β-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation (2002) 105(14):1669-1671.
   PubMedGoogle Scholar
• VYSSOULIS GP, MARINAKIS AG, AZNAOURIDIS KA et al.: The impact of third-generation β-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am. J. Hypertens. (2004) 17(7):582-589.
   PubMedGoogle Scholar
• CELIK T, YUKSEL UC, IYISOY A et al.: Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int. J. Cardiol. (2006) [Epub ahead of print].
   Google Scholar
• VAN BORTEL LM, BREED JG, JOOSTEN J, KRAGTEN JA, LUSTERMANS FA, MOOIJ JM: Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J. Cardiovasc. Pharmacol. (1993) 21(6):856-862.
   PubMedGoogle Scholar
• AMBROSIONI E, BACCHELLI S, ESPOSTI DD, BORGHI C: β-Blockade in hypertension and congestive heart failure. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 3):S25-S31.
   Google Scholar
• RIZOS E, BAIRAKTARI E, KOSTOULA A et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J. Cardiovasc. Pharmacol. Ther. (2003) 8(2):127-134.
   PubMedGoogle Scholar
• FOGARI R, ZOPPI A, LAZZARI P et al.: Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with Type II diabetes. J. Hum. Hypertens. (1997) 11(11):753-757.
   PubMed Web of Science ®Google Scholar
• PESSINA AC: Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 3):S33-S35.
   Google Scholar
• KAISER T, HEISE T, NOSEK L, ECKERS U, SAWICKI PT: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive Type 2 diabetic patients. J. Hypertens. (2006) 24(7):1397-1403.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MATERA MG, RUGGERI P et al.: Comparative effects of a 2-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration (2004) 71(2):159-64.
   PubMed Web of Science ®Google Scholar
• GALETTA F, FRANZONI F, MAGAGNA A et al.: Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy. Biomed. Pharmacother. (2005) 59(1-2):15-19.
   PubMedGoogle Scholar
• LU HR, REMEYSEN P, DE CLERCK F: Antiarrhythmic effects of nebivolol in experimental models in vivo. J. Cardiovasc. Pharmacol. (1994) 24:986-993.
   PubMedGoogle Scholar
• BRIXIUS K, MIDDEKE M, LICHTENTHAL A, JAHN E, SCHWINGER RH: Nitric oxide, erectile dysfunction and β-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharmacol. Physiol. (2007) 34(4):327-331.
   PubMed Web of Science ®Google Scholar
• KAMALI F, HOWES A, THOMAS SHL et al.: A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonist cimetidine and ranitidine. Br. J. Clin. Pharmacol. (1997) 43:201-204.
   PubMed Web of Science ®Google Scholar
• DOBRE D, VAN VELDHUISEN DJ, MORDENTI G et al.: Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure (SENIORS) trial. Am. Heart. J. (2007): In press.
   PubMedGoogle Scholar
• WILLIAMS B, LACY PS, THOM SM et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 113(9):1213-1225.
   PubMed Web of Science ®Google Scholar
• MCENIERY CM, SCHMITT M, QASEM A et al.: Nebivolol increases arterial distensibility in vivo. Hypertension (2004) 44(3):305-310.
   PubMed Web of Science ®Google Scholar